Catalyst Dossier · compiled by CeliA 🧫

Vistagen Therapeutics, Inc. (VTGN)

Pharmaceutical Preparations · market cap $27M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
PH94B Nasal Spray	Phase 3	Social Anxiety Disorder
AV-101	Phase 2	Major Depressive Disorder
PH94B	Phase 2	Adjustment Disorder With Anxious Mood
Fasedienol Nasal Spray	Phase 3	Social Anxiety Disorder (SAD)
Fasedienol Nasal Spray - Fasedienol Nasal Spray	Phase 2	Social Anxiety Disorder

Price & technical context

3-month

-54.9%

6-month

-64.1%

12-month

-89.6%

52-wk range

$0.23–$4.90

vs 50-day MA

-54.3%

vs 200-day MA

-84.5%

Realized vol

217.5%

Max drawdown

-95.4%

Daily closes through 2026-07-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VTGN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.